Jason Coloma Sells 23,865 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 23,865 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $26.05, for a total transaction of $621,683.25. Following the completion of the transaction, the chief executive officer directly owned 319,079 shares of the company’s stock, valued at approximately $8,312,007.95. The trade was a 6.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Up 1.3%

MAZE opened at $27.02 on Friday. The firm has a market capitalization of $1.50 billion, a P/E ratio of -10.68 and a beta of 2.26. Maze Therapeutics, Inc. has a one year low of $10.98 and a one year high of $53.65. The company has a fifty day moving average price of $25.64 and a 200-day moving average price of $36.03. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Equities research analysts expect that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Maze Therapeutics during the fourth quarter valued at approximately $39,000. Ameritas Investment Partners Inc. raised its stake in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the last quarter.

Wall Street Analyst Weigh In

MAZE has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Guggenheim raised their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Truist Financial dropped their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. Wedbush boosted their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Finally, Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.